secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178947
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable
--------------------------------------------------------------------------------

- Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.
- Board approved 12% workforce reduction; expects severance charges of $0.9M–$1.2M in Q3 2025; cash runway extended through YE 2027.
- FT819 SLE/LN: First patient on fludarabine-free conditioning achieved DORIS at 12-month follow-up; first extrarenal SLE patient without conditioning achieved LLDAS at 3 & 6 months.
- FDA allowed IND for FT836 MICA/B-targeted CAR T-cell program; Phase 1 to test without conditioning chemotherapy in solid tumors.
- Ono collaboration extended for second solid tumor CAR T candidate through at least June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/0001193125-25-178947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer